EyePoint Pharmaceuticals (EYPT) News Today $6.35 -0.12 (-1.85%) Closing price 04:00 PM EasternExtended Trading$6.53 +0.18 (+2.90%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 13.6% - Here's What HappenedEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 13.6% - Still a Buy?February 19 at 10:14 PM | marketbeat.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)February 17 at 7:00 AM | globenewswire.comabrdn plc Purchases Shares of 230,745 EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)abrdn plc acquired a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 230,745 shares of the company's stock, valued at approximately $1,719,00February 11, 2025 | marketbeat.comScotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)February 7, 2025 | markets.businessinsider.comChardan Capital Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT)Chardan Capital restated a "buy" rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday.February 6, 2025 | marketbeat.comEyePoint Announces Positive 6-Month Data From Duravyu Trial For Diabetic Macular EdemaFebruary 6, 2025 | markets.businessinsider.comEyePoint stock jumps 10% on Duravyu study resultsFebruary 6, 2025 | msn.comEyePoint Pharmaceuticals Stock Gains 3% After Positive Phase 2 Trial ResultsFebruary 6, 2025 | markets.businessinsider.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by AnalystsEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been assigned a consensus recommendation of "Buy" from the ten brokerages that are presently covering the firm, Marketbeat reports. Ten analysts have rated the stock with a buy recommendation. The average 1-year target price amongFebruary 6, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 1-Year Low - Here's What HappenedEyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 1-Year Low - Here's What HappenedFebruary 5, 2025 | marketbeat.comCollegium appoints Nancy Lurker to board of directorsFebruary 5, 2025 | markets.businessinsider.comDURAVYU shows promise in Phase 2 trial for eye diseaseFebruary 5, 2025 | msn.comEyePoint's decline following positive data makes no sense, says analystFebruary 5, 2025 | investing.comEyePoint Pharmaceuticals stock sinks following clinical trial resultsFebruary 5, 2025 | msn.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest UpdateEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 10,340,000 shares, a growth of 9.9% from the December 31st total of 9,410,000 shares. Based on an average daily volume of 956,300 shares, the days-to-cover ratio is currently 10.8 days.February 2, 2025 | marketbeat.comEyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea RivalJanuary 30, 2025 | seekingalpha.comEyePoint to Present at Guggenheim SMID Cap Biotech ConferenceJanuary 30, 2025 | globenewswire.comStrong week for EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders doesn't alleviate pain of one-year lossJanuary 25, 2025 | finance.yahoo.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 6.1% Higher - Should You Buy?EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 6.1% - Should You Buy?January 22, 2025 | marketbeat.comResearch Analysts Issue Forecasts for EYPT FY2025 EarningsEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for EyePoint Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim expects that the company will post earnings peJanuary 22, 2025 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Sees Large Increase in Short InterestEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 10,340,000 shares, a growth of 9.9% from the December 15th total of 9,410,000 shares. Based on an average daily volume of 956,300 shares, the short-interest ratio is currently 10.8 days.January 20, 2025 | marketbeat.comJPMorgan Chase & Co. Raises Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)JPMorgan Chase & Co. boosted its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 1,171.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 371,758 shares of the company's stJanuary 20, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 3.4% - Should You Buy?EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 3.4% Higher - What's Next?January 16, 2025 | marketbeat.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)January 16, 2025 | globenewswire.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of "Buy" from AnalystsShares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have earned an average rating of "Buy" from the ten analysts that are presently covering the firm, MarketBeat reports. Ten investment analysts have rated the stock with a buy rating. The average 1 year price target among brokJanuary 12, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 9.8% - Here's WhyEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 9.8% - Should You Sell?January 10, 2025 | marketbeat.comEyePoint Pharmaceuticals Strengthens Board with New AppointmentJanuary 9, 2025 | markets.businessinsider.comEyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of DirectorsJanuary 8, 2025 | markets.businessinsider.comOptimistic Buy Rating for EyePoint Pharmaceuticals: Potential of Duravyu in Diabetic Macular EdemaJanuary 8, 2025 | markets.businessinsider.comEyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.January 8, 2025 | globenewswire.comCitigroup Initiates Coverage of EyePoint Pharmaceuticals (EYPT) with Buy RecommendationJanuary 8, 2025 | msn.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up - Here's What HappenedEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up - Here's WhyJanuary 7, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Now Covered by Analysts at CitigroupCitigroup initiated coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday. They set a "buy" rating and a $33.00 target price for the company.January 7, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 9.6% - Here's What HappenedEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 9.6% - Here's WhyJanuary 6, 2025 | marketbeat.comPositive Outlook for EyePoint Pharmaceuticals Driven by Promising Prospects in the DME MarketJanuary 2, 2025 | markets.businessinsider.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Purchased by Geode Capital Management LLCGeode Capital Management LLC boosted its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 16.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,199,056 sharJanuary 2, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 5.8% - What's Next?EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 5.8% - Here's WhyDecember 31, 2024 | marketbeat.comBarclays PLC Grows Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Barclays PLC increased its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 410.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 245,045 shares of the company's stoDecember 27, 2024 | marketbeat.comFranklin Resources Inc. Buys 362,399 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Franklin Resources Inc. increased its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 9.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,012,048 shareDecember 19, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 6.4% - Here's WhyEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 6.4% - Here's What HappenedDecember 17, 2024 | marketbeat.comEyePoint to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2024 | markets.businessinsider.comShort Interest in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Decreases By 6.4%EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 9,250,000 shares, a drop of 6.4% from the November 15th total of 9,880,000 shares. Based on an average daily volume of 855,700 shares, the days-to-cover ratio is currently 10.8 days.December 16, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 52-Week Low - Should You Sell?EyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 52-Week Low - Should You Sell?December 16, 2024 | marketbeat.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)December 16, 2024 | globenewswire.comPoint72 Asset Management L.P. Cuts Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Point72 Asset Management L.P. lessened its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 28.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 451,318 shares of the company's stock after selling 179,451 shares duringDecember 9, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 7% Higher - Time to Buy?EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 7% - Here's WhyDecember 6, 2024 | marketbeat.comEyePoint Pharmaceuticals Poised for Growth with Promising DME Treatment DuravyuDecember 4, 2024 | markets.businessinsider.comPatient Square Capital LP Makes New $10.88 Million Investment in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Patient Square Capital LP purchased a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,361,979 shares of the cDecember 4, 2024 | marketbeat.comEyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular DegenerationDecember 4, 2024 | globenewswire.comConnor Clark & Lunn Investment Management Ltd. Sells 71,796 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Connor Clark & Lunn Investment Management Ltd. lessened its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 59.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 48,791 shares of the company's stock after selling 71,796 sharDecember 1, 2024 | marketbeat.com Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address EYPT Media Mentions By Week EYPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EYPT News Sentiment▼0.340.58▲Average Medical News Sentiment EYPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EYPT Articles This Week▼24▲EYPT Articles Average Week Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TXG News TRNS News SENS News CTKB News LAB News ALNT News AEHR News QTRX News QSI News NAUT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EYPT) was last updated on 2/20/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredFeb. 26 Could Send Nvidia’s “Silent Partners” SoaringNvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EyePoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EYPT Stock Alerts